Arivin Therapeutics
Arivin Therapeutics is a Finnish biotech company founded in 2022, headquartered in Espoo. The company specializes in developing innovative anti-virulence therapies aimed at treating antimicrobial-resistant (AMR) infections. Unlike traditional antibiotics that kill bacteria directly, Arivin's approach targets bacterial virulence factors—such as toxins and biofilms—to disarm pathogens without promoting resistance. This strategy is particularly beneficial for patients with conditions like cystic fibrosis, bronchiectasis, COPD, sepsis, and chronic wounds, where conventional antibiotics often fail .
Arivin Therapeutics is a Finnish biotech company founded in 2022, headquartered in Espoo. The company specializes in developing innovative anti-virulence therapies aimed at treating antimicrobial-resistant (AMR) infections. Unlike traditional antibiotics that kill bacteria directly, Arivin's approach targets bacterial virulence factors—such as toxins and biofilms—to disarm pathogens without promoting resistance. This strategy is particularly beneficial for patients with conditions like cystic fibrosis, bronchiectasis, COPD, sepsis, and chronic wounds, where conventional antibiotics often fail .